BKC,

I saw that PLoS One article today too. The only BET inhibitors they actually mention are JQ1 and I-BET151. Not only did they omit mention of RVX-208, but they failed to mention hardly any of the BET inhibitors in the clinic. Furthermore, they don't even discuss bromodomain-specific inhibition. I wouldn't classify this as a knock against Resverlogix. I would file this away as a poorly cited article in which the authors failed to do their homework in searching for current literature and clinical trials.

BearDownAZ